(Albany, United States) As per DelveInsight’s assessment, globally, the Thyroid Cancer Pipeline constitutes 40+ key companies continuously working towards developing 40+ Thyroid Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Thyroid Cancer Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Thyroid Cancer NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Thyroid Cancer Pipeline treatment landscape of the report, click here @ Thyroid Cancer Pipeline Outlook

 

Key Takeaways from the Thyroid Cancer Pipeline Report

• DelveInsight’s Thyroid Cancer Pipeline analysis depicts a robust space with 40+ active players working to develop 40+ pipeline treatment therapies.
• The leading companies working in the Thyroid Cancer Market include Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
• Promising Thyroid Cancer Pipeline Therapies in the various stages of development include Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
• On January 2023, Famewave Ltd announced a study of phase 1 & 2 clinical trials for Nivolumab and Nal-IRI/5-FU/LV – Expansion. This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C & D) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV will be administered subsequent to CM24 and nivolumab. CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.
• In July 2023, Eisai Limited announced a study of phase 1 & 2 clinical trials for Lenvatinib, Ifosfamide, and Etoposide. This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid malignancies including differentiated thyroid carcinoma (single agent lenvatinib) and osteosarcoma (single agent and combination lenvatinib).

 

Thyroid Cancer Overview

Thyroid cancer starts in the cells that make up your thyroid gland. The thyroid gland makes hormones that help control many processes in your body. Thyroid cancer is relatively common enough so that all of us will know somebody with thyroid cancer.

 

For further information, refer to the detailed Thyroid Cancer Unmet Needs, click here for Thyroid Cancer Ongoing Clinical Trial Analysis

 

Thyroid Cancer Emerging Drugs Profile

• Donafenib: Suzhou Zelgen Biopharmaceuticals
• Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
• Nivolumab: Bristol-Myers Squibb
• RX208: Suzhou NeuPharma
• AIC100: AffyImmune Therapeutics

 

Thyroid Cancer Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the therapies for Thyroid Cancer. The companies which have their Thyroid Cancer drug candidates in the most advanced stage, i.e. phase III include, Suzhou Zelgen Biopharmaceuticals.

 

Request a sample and discover the recent advances in Thyroid Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Thyroid Cancer Segmentation

 

Thyroid Cancer Drugs and Companies

• Rosiglitazone: Exelixis
• Lenvatinib: Eisai Limited
• Ifosfamide: Merck Sharp & Dohme LLC

 

Thyroid Cancer Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Thyroid Cancer Therapeutics Market include-

Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.

 

Dive deep into rich insights for drugs for Thyroid Cancer Pipeline, click here @ Thyroid Cancer Unmet Needs and Analyst Views

 

Scope of the Thyroid Cancer Pipeline Report

• Coverage- Global
• Companies- Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
• Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Thyroid Cancer Merger and acquisitions, Licensing Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Thyroid Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Thyroid Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Donafenib: Suzhou Zelgen Biopharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nivolumab: Bristol-Myers Squibb
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AIC100: Affyimmune Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Thyroid Cancer Key Companies
21. Thyroid Cancer Key Products
22. Thyroid Cancer- Unmet Needs
23. Thyroid Cancer- Market Drivers and Barriers
24. Thyroid Cancer- Future Perspectives and Conclusion
25. Thyroid Cancer Analyst Views
26. Thyroid Cancer Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services